Lanthanum　(La)-based　nanotherapeutics　are　therapeutically　advantageous　due　to　cytoplasmic　oxygen　species　(ROS)　levels　for　mediating　intrinsic　and　extrinsic　tumor　cell　apoptosis.　While　they　have　not　been　extensively　explored　for　their　potential　to　suppress　malignancies　in　vivo.　Correspondingly,　we　have　formulated　a　unique　lanthanum　nanocarrier　with　high　specific　surface　area,　dendritic-divergent　mesopores,　importantly,　exposing　more　active　lanthanum　sites.　After　surface　PEGlytion　and　ICG　loading　in　mesoporous　channels,　this　fantastic　nanoplatform　can　efficaciously　enrich　in　malignant　glioblastoma　regions.　Meaningfully,　it　can　be　sensitively　dissociated　for　La　ions　release　under　weak　acid　(pH　=　6.5)　tumor　microenvironment.　Upon　808　nm　light　irradiation,　high　light-heat　conversion　efficiency　is　further　proved,　then　this　satisfied　thermal　in　the　tumor　site　progressively　enhances　ROS　production　by　La　ions.　Owing　to　the　synergistic　oxidative　therapy　and　photothermal　therapy　of　our　dendritic　La　nanoplatform,　glioblastoma　is　efficaciously　and　synergistically　prevented　both　in　vitro　and　in　vivo.　All　outcomes　highlight　the　therapeutic　potency　of　La　based　nanoplatform　with　radial　mesopores　to　treat　malignant　cancer　in　vivo　and　encourage　future　translational　exploration.